Oncology & Cancer

Five-year extended hormone therapy no better in breast cancer

(HealthDay)—Extending hormone therapy by five years does not provide benefit over a two-year extension among postmenopausal women with hormone receptor-positive breast cancer who had received five years of adjuvant endocrine ...

Oncology & Cancer

Smoking cessation after NSCLC diagnosis cuts mortality risk

(HealthDay)—For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according ...

Oncology & Cancer

New concept drug hunts down late-stage prostate cancer

A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumor cells, is well tolerated by patients and keeps them ...

Oncology & Cancer

Radioligand therapy slows advanced PSMA+ prostate cancer

(HealthDay)—Lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, ...

Oncology & Cancer

Stem cell transplant reviewed for peripheral T-cell lymphoma

(HealthDay)—For patients with refractory or relapsed peripheral T-cell lymphoma (R/R-PTCL), three- and five-year overall survival (OS) and progression-free survival (PFS) are similar with allogeneic or autologous hematopoietic ...

page 1 from 9